• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD.

作者信息

Porsbjerg Celeste, Maitland-van der Zee Anke H, Brusselle Guy, Canonica Giorgio Walter, Agusti Alvar, Faner Rosa, Vogelmeier Claus F, Nawijn Martijn, van den Berge Maarten, Rusconi Franca, Pilette Charles, Ramiconi Valeria, Coleman Courtney, Chaudhuri Rekha, Chung Kian Fan, Wedzicha Jadwiga, Saglani Sejla, Van der Schee Marc P, Heaney Liam, Bourdin Arnaud, Roberts Graham, Djukanovic Ratko, Kuna Piotr, Kupczyk Maceij, Axmann Judith, Staudinger Heribert, Clarke Graham W, Dahlen Sven Erik, Brightling Chris

机构信息

Dept of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen, Denmark

Copenhagen Center for Translational Research, Bispebjerg Hospital, Copenhagen, Denmark.

出版信息

Eur Respir J. 2021 Oct 21;58(4). doi: 10.1183/13993003.02168-2021. Print 2021 Oct.

DOI:10.1183/13993003.02168-2021
PMID:34675035
Abstract
摘要

相似文献

1
3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD.3TR：一个泛欧洲跨疾病研究联盟，旨在改善哮喘和慢性阻塞性肺疾病的个性化生物治疗。
Eur Respir J. 2021 Oct 21;58(4). doi: 10.1183/13993003.02168-2021. Print 2021 Oct.
2
Identification of Asthma-COPD Overlap, Asthma, and Chronic Obstructive Pulmonary Disease Phenotypes in Patients with Airway Obstruction: Influence on Treatment Approach.气道阻塞患者中哮喘-COPD 重叠、哮喘和慢性阻塞性肺疾病表型的鉴定：对治疗方法的影响。
Respiration. 2020;99(1):35-42. doi: 10.1159/000503328. Epub 2019 Nov 6.
3
Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap.哮喘-慢性阻塞性肺疾病重叠综合征的治疗方法
Expert Rev Clin Immunol. 2017 May;13(5):449-455. doi: 10.1080/1744666X.2017.1273109. Epub 2016 Dec 26.
4
Differences in Adherence Barriers to Inhaled Medicines between Japanese Patients with Chronic Obstructive Pulmonary Disease and Asthma Evaluated using the "Adherence Starts with Knowledge 20" (ASK-20) Questionnaire.使用“依从性始于知识20”（ASK - 20）问卷评估日本慢性阻塞性肺疾病患者和哮喘患者吸入药物依从性障碍的差异。
Intern Med. 2019 Jan 15;58(2):175-185. doi: 10.2169/internalmedicine.0488-17. Epub 2018 Sep 12.
5
Personalised Medicine for Asthma and Chronic Obstructive Pulmonary Disease.哮喘和慢性阻塞性肺疾病的个性化医疗
Respiration. 2017;93(3):153-161. doi: 10.1159/000455395. Epub 2017 Jan 21.
6
Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey.慢性阻塞性肺疾病（COPD）队列中哮喘-COPD重叠综合征患者的治疗趋势：一项真实世界调查的结果
Int J Chron Obstruct Pulmon Dis. 2017 Jun 15;12:1753-1763. doi: 10.2147/COPD.S136314. eCollection 2017.
7
Study to Evaluate Satisfaction with the Inhalation Device Used by Patients with Asthma or Chronic Obstructive Pulmonary Disease and the Association with Adherence and Disease Control.评估哮喘或慢性阻塞性肺疾病患者对吸入装置的满意度研究及其与依从性和疾病控制的关系。
J Aerosol Med Pulm Drug Deliv. 2020 Jun;33(3):153-160. doi: 10.1089/jamp.2019.1541. Epub 2019 Dec 13.
8
Possible maximal change in the SF-36 of outpatients with chronic obstructive pulmonary disease and asthma.慢性阻塞性肺疾病和哮喘门诊患者SF-36可能的最大变化。
J Asthma. 2004;41(3):355-65. doi: 10.1081/jas-120026095.
9
Redefining the overlap of asthma and COPD.重新定义哮喘与慢性阻塞性肺疾病的重叠
Drug Ther Bull. 2017 Jul;55(7):66-69. doi: 10.1136/dtb.2017.7.0505.
10
Specific, but not general beliefs about medicines are associated with medication adherence in patients with COPD, but not asthma: Cohort study in a population of people with chronic pulmonary disease.特定而非一般的药物信念与 COPD 患者的药物依从性相关，但与哮喘无关：慢性肺部疾病人群的队列研究。
J Psychosom Res. 2018 Apr;107:46-52. doi: 10.1016/j.jpsychores.2018.02.004. Epub 2018 Feb 8.

引用本文的文献

1
Spatial Eosinophil Phenotypes as Immunopathogenic Determinants in Inflammatory Diseases.作为炎症性疾病免疫致病决定因素的空间嗜酸性粒细胞表型
Cells. 2025 Jun 5;14(11):847. doi: 10.3390/cells14110847.
2
Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma.生物制剂治疗前的疾病轨迹与重度哮喘的发病负担及生物制剂治疗反应相关。
Eur Respir J. 2025 Apr 3;65(4). doi: 10.1183/13993003.01497-2024. Print 2025 Apr.
3
Airway remodelling in asthma and the epithelium: on the edge of a new era.
哮喘和上皮细胞中的气道重塑：新时代的边缘。
Eur Respir J. 2024 Apr 18;63(4). doi: 10.1183/13993003.01619-2023. Print 2024 Apr.
4
Definition, Phenotyping of Severe Asthma, Including Cluster Analysis.定义、严重哮喘的表型分析，包括聚类分析。
Adv Exp Med Biol. 2023;1426:239-252. doi: 10.1007/978-3-031-32259-4_11.
5
Characteristics of severe asthma patients on biologics: a real-life European registry study.接受生物制剂治疗的重度哮喘患者的特征：一项欧洲真实世界注册研究
ERJ Open Res. 2023 May 2;9(3). doi: 10.1183/23120541.00586-2022. eCollection 2023 Jul.
6
Precision Medicine in Asthma Therapy.哮喘治疗中的精准医学。
Handb Exp Pharmacol. 2023;280:85-106. doi: 10.1007/164_2022_598.